US Patent

US11596634 — Lamotrigine oral liquid suspension and use thereof

Method of Use · Assigned to OWP Pharmaceuticals Inc · Expires 2040-05-29 · 14y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects an oral liquid suspension of lamotrigine and methods of medical treatment using the suspension.

USPTO Abstract

The present invention relates to an oral liquid suspension that includes lamotrigine and methods of medical treatment that include administering the oral liquid suspension. The oral liquid suspension has desirable physicochemical properties and technical attributes. The oral liquid suspension is useful in patients having difficulties in swallowing tablets and provide medical practitioners with additional options for dose titration.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4271 — Lamictal

Patent Metadata

Patent number
US11596634
Jurisdiction
US
Classification
Method of Use
Expires
2040-05-29
Drug substance claim
No
Drug product claim
No
Assignee
OWP Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.